April 4, 2022

Several years following FDA approval, Ibsrela® (tenapanor) oral tablets are now available to treat irritable bowel syndrome with constipation (IBS-C) in adults.

  • Ibsrela is a first-in-class treatment for IBS-C that received FDA approval on September 12, 2019. However, manufacturer Ardelyx has only recently launched the product.
  • Recommended dosing is 50mg taken twice daily by mouth: once immediately prior to breakfast or the first meal of the day, and once immediately prior to dinner.
  • The wholesale acquisition cost (WAC) is $1,500 per 60 tablets.
May 1, 2022

Brand Medications with Generic Alternatives Anticipated to be Approved in May

Read More
April 25, 2022

Veklury Approved to Treat COVID-19 in Younger Patient Population

Read More
April 22, 2022

Pfizer Recalls Five Lots of Accupril

Read More
April 21, 2022

Zerbaxa Now Indicated for Children

Read More